MEDICAL DEVICES

MedTech Company STENTiT Raises €1.8 million in Seed Round

STENTiT | April 25, 2022

MedTech Company

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency and the Ten Cate Investment Company.

STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution.

As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients.

With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year.

"We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation."

Bart Sanders, CEO of STENTiT

 

About STENTiT

STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out.

Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world.

Spotlight

To achieve maximum success and profitability, practices must be efficient while providing the best care. Fortunately, technology provides tools you need to optimize your practice and convenience to patients. Learn how video visits drive efficiency...

Spotlight

To achieve maximum success and profitability, practices must be efficient while providing the best care. Fortunately, technology provides tools you need to optimize your practice and convenience to patients. Learn how video visits drive efficiency...

Related News

FUTURE OF HEALTHCARE

Medline Announces the Launch of Two Healthcare Sustainability Programs

Medline | December 03, 2020

Medline today announced two new medical care maintainability programs. The projects, a Green Product Portfolio and a Sustainable Packaging Lab, will assist medical clinics with decreasing the measure of product squander emerging from their offices. As per an ongoing industry report, the United States is the world's most noteworthy producer of medical care greenhouse gases, representing 27% of the worldwide medical care footprint. "More and more, we are hearing directly from hospitals that they understand the negative consequence their environmental footprint can have on their patient population," said Hannah Anderson, Medline sustainability specialist. "There is a culture change happening to find ways to make their supply chain more sustainable. Being a primary medical supplier partner, we are well positioned to help customers develop meaningful and actionable strategies to improve the health of patients in the communities they serve through sustainability." Green products portfolio Medline is introducing a new web page to help make it easier for healthcare providers to find and purchase green products. The company currently has over 40 unique product types that meet Medline's Green Product Portfolio Standards, which are informed by Kaiser Permanente's Environmentally Preferred Purchasing guidelines, the Federal Trade Commission's Green Guides, and the Environmental Protection Agency's guidelines. Hospitals can explore products within three key focus areas: Environmental services: From wipes to disinfectants, Medline's green options are Green Seal certified and contain fewer chemicals of concern to help minimize the risk of harm to human health and the environment. Healthcare essentials: Essential products like patient gowns, dinnerware and even plastic cups, are consumed at a rapid rate within healthcare. These green essentials products are designed to incorporate more sustainable materials. Perioperative care: Operating rooms produce more than 2,000 tons of waste per day. Medline's suite of products including surgical towels, procedural trays and fluid management systems help minimize waste in a cost-effective manner. Reducing product-packaging waste The Healthcare Plastics Recycling Council estimates that 2,800 to 3,500 tons of plastic packaging product waste is generated daily by U.S. healthcare facilities. To help reduce material use and waste, Medline is unveiling a Sustainable Packaging Lab, a cross-functional group consisting of employees who specialize in research and development, engineering, packaging and product design. The group will tackle packaging waste from every step of the process and aims to complete and roll out four new projects by the end of 2021. About Medline Medline is a healthcare company: a manufacturer, distributor and solutions provider focused on improving the overall operating performance of healthcare. Medline works with both the country's largest healthcare systems and independent facilities across the continuum of care to provide the clinical and supply chain resources required for long-term financial viability in delivering high quality care. With the size of one of the country's largest companies and the agility of a family-owned business, Medline is able to invest in its customers for the long-term and rapidly respond with customized solutions. Headquartered in Northfield, Ill., Medline has 27,000+ employees worldwide, a fleet of nearly 1,000 trucks and does business in more than 90 countries.

Read More

AI

Eyenuk Launches EyeArt AI System in South Africa in Collaboration with Discovery Health

Eyenuk, Inc. | December 08, 2021

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announces today that Discovery Health launched a new Diabetic Retinopathy Screening Benefit nationwide in South Africa, powered by the cutting-edge EyeArt® AI System helping enable the detection of the onset of diabetic retinopathy as early as possible. By launching the new Diabetic Retinopathy Screening Benefit, Discovery Health Medical Scheme (DHMS) simplifies access to screening for diabetic retinopathy and introduces cutting-edge AI-driven technology to the process. The Diabetic Retinopathy Screening Benefit follows a simple, three-level process: primary grading by the EyeArt AI System, and if required, secondary grading by an optometrist, and tertiary grading by an ophthalmologist. “Discovery Health has always focused on incentivising, simplifying and enhancing member access to evidence-based preventative healthcare screening,” says CEO of Discovery Health, Dr. Ryan Noach. “The DHMS Diabetic Retinopathy Screening Benefit is fully aligned to this ethos. It gives members easy access to annual screening, which is conducted using cutting-edge AI technology, followed up by a clear referral process, and supported by scheme benefits requiring no member out-of-pocket payments for primary and secondary grading. Through this benefit, we hope to increase the number of DHMS members who are screened for diabetic retinopathy.” “We applaud Discovery Health’s leadership for being the first payor to bring our EyeArt AI system to South Africa. The EyeArt AI System is the most extensively validated and adopted AI system for autonomous diabetic retinopathy detection in real-world settings. It has been cleared by regulatory authorities around the world, including the U.S. Food and Drug Administration (FDA), and is reimbursed by government and private payors in the U.S.” Frank Cheng, Eyenuk President and CCO Dr. Patrick Godard, Chief Commercial Officer at Vertice MedTech, commented, “Diabetic Retinopathy is a growing problem, and Artificial Intelligence (AI) in medical diagnostics signals a new era. Vertice EyeCare is excited to offer the cutting-edge EyeArt AI system in South Africa. The EyeArt AI system provides automated screening in a single office visit by utilising AI algorithms to assess retina images in compliance with international standards. Early identification and treatment can reduce the burden of sight-threatening retinopathy, allowing clinicians to identify patients who require immediate medical treatment without having to worry about mydriasis. Vertice MedTech believes that deploying world-class healthcare innovations such as the EyeArt AI system allows for optimising patient treatment and care.” About Discovery Discovery Limited is a South African-founded financial services organisation that operates in the healthcare, life assurance, short-term insurance, savings and investment and wellness markets. Since inception in 1992, Discovery has been guided by a clear core purpose – to make people healthier and to enhance and protect their lives. This has manifested in its globally recognised Vitality Shared-Value insurance model, active in 31 markets with over 20 million members. The model is exported and scaled through the Global Vitality Network, an alliance of some of the largest insurers across key markets including AIA (Asia), Ping An (China), Generali (Europe), Sumitomo (Japan), John Hancock (US), Manulife (Canada), among others. Discovery trades on the Johannesburg Securities Exchange as DSY. About Vertice MedTech Vertice MedTech is a collection of South African companies with specialist skill sets, an established track record with defined medical focus areas with many years of practical skill and with experience in several medical specialities, which it offers to identified stakeholders to achieve best medical industry practise and best possible healthcare delivery to African patients. Vertice’s medium-term strategy is to become the leading specialised MedTech group in South Africa and Sub-Saharan Africa. This strategy is being implemented through a buy and build investment thesis augmented by digitisation and support function optimisation. Ethos and the Vertice management team are working together to ensure that Vertice implements operational excellence for each of Vertice’s businesses and has the resources (people, capital, etc) to successfully execute the strategy and establish governance that embeds executive freedom within accountability to the board. About Eyenuk, Inc. Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. About the EyeArt AI System The EyeArt AI System provides fully autonomous diabetic retinopathy (DR) screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds. The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to U.S. Food and Drug Administration (FDA) 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

Read More

HEALTH TECHNOLOGY

One Touch Telehealth Launches Version 5.0 Beyond Virtual Care

One Touch Telehealth | November 11, 2020

One Touch Telehealth reports its new programming discharge, Version 5.0: "Beyond Virtual Care." Carrie Chitsey, Co-Founder and CEO says that, "With the expansion in video telehealth in the midst of COVID-19, virtual care is setting down deep roots. We optimized our new delivery given the 500%+ expansion in the utilization of video telehealth from our customer base and bits of knowledge from our clients on what they should be effective in virtual patient work processes." Most healthcare associations are right now attempting to keep up routine arrangements, procure new patients, and protect their patients and clinicians. The new delivery goes beyond a 1:1 video call to increment operational efficiencies inside telehealth work processes. With our new delivery, healthcare associations can recreate an in-person work process and virtually registration, do graph survey with the attendant, see their supplier, and registration, all in a solitary video counsel. We've united everything to upgrade the work process in one video call both for the patient and clinician experience. One Touch Telehealth is facilitating an online class for healthcare associations, "Best Practices: Virtual Patient Handoff Workflow." We talk about how to go beyond 1:1 video calls to increment operational efficiencies inside telehealth work processes. One Touch Telehealth's patient survey data revealed that 95% of patients were "very" or "somewhat likely" to want to see their provider through video telehealth again. "Healthcare organizations have to think about telehealth as a long-term strategy in the future 'hybrid model' of patient interactions," says Co-Founder and CEO Carrie Chitsey. As video telehealth turns into the new ordinary in each part of life, One Touch Telehealth drives the telehealth business through driving selection and change. Version 5.0 New Feature Highlights Image Capture: Take high-resolution (4K) photos at the click of a button during the telehealth visit. Connection Health Meter: See patient and providers bandwidth, camera resolution, and other parameters in real-time to optimize video quality and connectivity. In-Video Messaging: Send messages in real-time with patients or other clinicians on the call, privately or to the group. In-Video Secure Link: Send secure links to patients, such as online documents, new patient paperwork, instructions, or a payment link. Multi-Party Connect: Transfer calls to other clinicians, front office, or nursing staff within your organization for workflow efficiency. Ability to add external parties such as caregivers, case managers, or care teams. Screen Share: Share the contents of your screen to review items such as test results, digital coaching, or education. About One Touch Telehealth One Touch Telehealth was founded on the principles of making the best telehealth platform affordable to any healthcare organization allowing them to provide proactive and immediate virtual care anywhere and everywhere. We strive daily to improve the clinician and patient experience for all demographics, with our Click. Click. Connect simplicity. We make it possible to plug into your existing workflows with white-labeled patient experience.

Read More